hackint0sh/New-Dataset huggingface dataset:
This is two-armed pilot randomized controlled trial taking place in an inpatient neurologic rehabilitation clinic. A total of 30 persons that are undergoing inpatient rehabilitation due to a stroke will be randomly assigned to either the intervention group (IG) or the control group (CG). Participants of the IG will receive exergame-based motor-cognitive training on a labile surface, whereas participants of the CG will train on a stable surface. Primary outcome is feasibility comprising measures of adherence, attrition, safety and usability. Secondary outcomes will be measures of cognitive (psychomotor speed, inhibition, selective attention, cognitive flexibility, brain activity) and motor (functional mobility, gait speed, balance, proprioception) functioning. conditions: Stroke studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 30 type: ESTIMATED name: exergame-based cognitive-motor training on an unstable surface name: exergame-based cognitive-motor training on an stable surface measure: Security incidents measure: Attrition rate measure: Adherence rate measure: Usability measure: Training Load measure: Enjoyment measure: User experience measure: Training Goals measure: Changes in cognitive flexibility measure: Changes in psychomotor speed measure: Changes in selective attention measure: Changes in inhibition and brain activity measure: Changes in functional mobility measure: Changes in coordination measure: Changes in dynamic balance measure: Changes in static balance measure: Changes in gait measure: Changes in leg proprioception measure: Changes in balance confidence measure: Changes in gait confidence sex: ALL minimumAge: 50 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Rehaklinik Zihlschlacht status: RECRUITING city: Zihlschlacht-Sitterdorf state: Thurgau zip: 8588 country: Switzerland name: Detlef Marks role: CONTACT phone: 071 424 37 51 lat: 47.51401 lon: 9.26776 hasResults: False
nctId: NCT06296056 id: SDH-combi briefTitle: Phase I Study of Combined Immune Cell Therapy in Patients With Stage 4 Colorectal Cancer With Metastatic Lesion Who Failed Prior Standard of Care overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2025-12-01 date: 2027-06-01 date: 2024-03-06 date: 2024-03-06 name: Nyamdavaa Tuul class: OTHER briefSummary: To evaluate the safety, immune response, and potential efficacy of combined immune cell therapy in patients with stage 4 colorectal cancer who have failed standard treatment and have unresectable lesions or metastatic lesions. conditions: Colorectal Cancer Stage IV conditions: Metastatic Colorectal Cancer studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 20 type: ESTIMATED name: Combi measure: Number of Patients with grade 1-5 adverse events and list of adverse event frequency measure: immune response measure: potential efficacy sex: ALL minimumAge: 19 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06296043 id: SBU-FUT-01 briefTitle: The Effect of Su-Jok Application and Progressive Muscle Relaxation Exercises in Coping With Premenstrual Syndrome overallStatus: NOT_YET_RECRUITING date: 2024-04-10 date: 2024-07-15 date: 2024-08-15 date: 2024-03-06 date: 2024-04-01 name: Saglik Bilimleri Universitesi class: OTHER briefSummary: The aim of this study is to determine the effect of su-jok application and progressive muscle relaxation exercise in coping with premenstrual syndrome. conditions: Premenstrual Syndrome studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Three groups with su-jok group, progressive muscle relaxation exercise group and control group primaryPurpose: SUPPORTIVE_CARE masking: SINGLE maskingDescription: Double (Participant, Outcomes Assessor) Since the application will be performed by the researcher, participant will be blinded in this study. The statistician will be blinded in the evaluation of the data. whoMasked: PARTICIPANT count: 135 type: ESTIMATED name: Progressive Muscle Relaxation Exercise Group name: Su-Jok Intervention measure: PAIN Visual Analog Scale (VAS)- (Min:0 - Max:10) measure: FATIGUE Visual Analog Scale (VAS)- (Min:0 - Max:10) measure: SLEEP STATE Visual Analog Scale (VAS)- (Min:0 - Max:10) measure: NAUSEA VOMITING Visual Analog Scale (VAS)- (Min:0 - Max:10) measure: Change in Premenstrual Symptoms (People with PMS scale scores over 104 points will be determined). sex: FEMALE minimumAge: 18 Years maximumAge: 30 Years stdAges: ADULT hasResults: False
nctId: NCT06296030 id: 22-0010 briefTitle: Culturally Tailored ACT for Black Trauma overallStatus: WITHDRAWN date: 2021-09-01 date: 2022-09-01 date: 2023-08-31 date: 2024-03-06 date: 2024-03-06 name: Azusa Pacific University class: OTHER briefSummary: Blacks in America more frequently meet the criteria for posttraumatic stress disorder (PTSD) than any other US race or ethnicity. Yet, blacks are among the groups least likely to use mental health services for trauma. Thus, a large number of traumatized blacks suffer silently and remain untreated.
Acceptance and Commitment Therapy (ACT) is an empirically-based psychological intervention that uses acceptance and mindfulness strategies, with commitment and behavior change strategies, to increase psychological flexibility and decrease anxiety outcomes. While culturally tailored mental health interventions have been shown useful for racial and ethnic minorities, there have been few efforts to tailor ACT for blacks. This NIH R21 would compare an ACT model specifically culturally tailored for blacks (POOF) to the classic ACT model in a randomized trial, where clinicians will conduct 12-session telehealth synchronous virtual groups. Eighty black participants who self-identify as suffering from stress or anxiety will be confidentially recruited. Two specific aims are proposed:
The proposed R21 pilot study will be the first randomized controlled trial to evaluate an ACT intervention tailored explicitly for black racial trauma. This study will provide critical data needed to plan and design a future R01 controlled longitudinal effectiveness study. The long-term objective is to significantly reduce the prevalence of stress and anxiety-related symptoms due to traumatic events for Blacks by increasing treatment acceptability for this population. Since blacks have the highest rates of trauma prevalence and chronicity, yet they are still underrepresented in mental health treatment, this tailored intervention can have a significant public health impact. conditions: Stress Disorders, Traumatic conditions: Anxiety conditions: Anxiety Disorders studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: FACTORIAL interventionModelDescription: This project's research design is a two-by-two factorial design. Factor one, the type of ACT intervention delivered, has two levels - POOF delivery (level 1) and a classic ACT delivery (level 2). Factor two, the facilitator's first group treatment delivery, also has two levels. There are four (4) group facilitators. The first two facilitators deliver traditional ACT first (level 1), and the second two facilitators deliver POOF first (level 2). Each facilitator providing group treatment will facilitate two groups (classic and POOF), one after the next. However, facilitators will be randomized to the order in which they deliver their first group to reduce experimenter/ clinician history bias. All of the facilitators are licensed, mental health clinicians. primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER count: 0 type: ACTUAL name: POOF ACT program name: Classic ACT program measure: Race-Based Traumatic Stress sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Azusa Pacific University city: Azusa state: California zip: 91702 country: United States lat: 34.13362 lon: -117.90756 hasResults: False
nctId: NCT06296017 id: AEŞH- EK1- 2023-115 briefTitle: Effectiveness of Conservative Interventions in the Treatment of Trigger Finger overallStatus: RECRUITING date: 2023-10-02 date: 2024-09 date: 2024-12 date: 2024-03-06 date: 2024-04-29 name: Hacettepe University class: OTHER briefSummary: There is no study in the literature comparing the effectiveness of ESWT and splint therapy, which are the most commonly used approaches in the treatment of Trigger Finger (TF). The aim in this study is to investigate the effectiveness of ESWT and splint therapy used in the treatment of TF. conditions: Trigger Finger conditions: Stenosing Tenosynovitis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 54 type: ESTIMATED name: Experimental: Extracorporeal Shock Wave Therapy name: Trigger Finger Splint name: Extracorporeal Shock Wave Therapy+ Trigger Finger Splint measure: Visual analog scale measure: Grip and pinch strength measure: Number of trigger measure: Functional assessment measure: Treatment satisfaction measure: Functional assessment sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Feray Karademir status: RECRUITING city: Ankara zip: 06100 country: Turkey name: Feray Karademir role: CONTACT phone: 90 505 313 75 82 email: karademirferay@gmail.com name: Feray Karademir role: CONTACT lat: 39.91987 lon: 32.85427 hasResults: False
nctId: NCT06296004 id: CAPILLAROSCOPY behcet disease briefTitle: Relation Between Nail Fold Capillaroscopy, Optical Coherence Tomography Angiography, and Femoral Vein Wall Thickness in Behçet's Disease Relation Between Nail Fold Capillaroscopy, Optical Coherence Tomography Angiography, and Femoral Vein Wall Thickness in Behçet's Disease overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2025-03-01 date: 2025-04-01 date: 2024-03-06 date: 2024-03-06 name: Assiut University class: OTHER briefSummary: Relation between Nail Fold Capillaroscopy, Optical Coherence Tomography Angiography, and Femoral Vein Wall Thickness in Behçet's Disease conditions: Behçet's Disease studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: PROSPECTIVE count: 80 type: ESTIMATED name: Nail Fold Capillaroscopy, Optical Coherence Tomography Angiography, and Femoral Vein Wall Thickness by U.S measure: measuring parameter of Nail Fold Capillaroscopy in behcet disease measure: measuring parameter of Optical Coherence Tomography Angiography in behcet disease measure: measuring parameter of Femoral Vein Wall Thickness in behcet disease measure: relation between Nail Fold Capillaroscopy and activity of behcet disease measure: relation between Optical Coherence Tomography Angiography and activity of behcet disease measure: relation between Femoral Vein Wall Thickness and activity of behcet disease sex: ALL minimumAge: 19 Years maximumAge: 60 Years stdAges: ADULT hasResults: False
nctId: NCT06295991 id: 2023/005 briefTitle: The Effect of Lycra Garments on Spastic Diplegic Cerebral Palsy Patients With Scoliosis overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2024-03-21 date: 2024-07-30 date: 2024-03-06 date: 2024-03-06 name: Hacettepe University class: OTHER briefSummary: The primary aim of this study was to investigate the effects of lycra clothing on balance and respiratory functions in individuals with cerebral palsy with scoliosis, and the secondary aim was to investigate the effects of lycra clothing on motor function, activity limitation and quality of life in these individuals. conditions: Balanced; Rearrangement conditions: Respiratory Function Test studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SCREENING masking: SINGLE whoMasked: PARTICIPANT count: 24 type: ESTIMATED name: Lycra garment measure: Balance parameters measure: Respiratory functions measure: Respiratory muscle strength measurement measure: Gross motor function measurement measure: Functional independence assessment measure: Assessment of activity restriction measure: Quality of life assessment measure: Assessment of posture sex: ALL minimumAge: 10 Years maximumAge: 18 Years stdAges: CHILD stdAges: ADULT hasResults: False
nctId: NCT06295978 id: 4896 briefTitle: Multimarker Approach in Acute Chest Pain overallStatus: RECRUITING date: 2021-02-01 date: 2024-05-31 date: 2024-12-31 date: 2024-03-06 date: 2024-03-06 name: Fondazione Policlinico Universitario Agostino Gemelli IRCCS class: OTHER briefSummary: Chest pain is one of the most common causes of access in the Emergency Room, and it can be a clinical manifestation of a broad spectrum of diseases including those 'time dependent' conditions such as acute coronary syndrome (ACS). Diagnosis or exclusion of acute myocardial infarction (AMI) is a daily challenge in the emergency department (ED), especially when classic clinical criteria and ECG alone are unable to make the diagnosis. The ED physician has the extremely delicate task of managing patients with chest pain and being able to frame them correctly; therefore, he needs to make differential diagnosis since chest pain can be caused by non-cardiac vascular events but also extra-cardiovascular events, such as pulmonary, neurological, osteoarticular, gastrointestinal and psychological. Recently, the importance of inflammatory processes and endothelial damage in cardiovascular disease has been highlighted, and consequently the focus has been on new markers, in a "multimarker" approach in which the strengths of each are combined together to provide an optimal solution to a clinical problem.
The data suggest how a future integration of these biomarkers in the routine approach to the patient with acute chest pain in the ED might allow a better patient stratification and proper management, allowing the clinician to make an early safe discharge or a timely admission for those who deserve in-depth diagnostic-therapeutic investigation. conditions: Cardiovascular Disease Other studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 250 type: ESTIMATED name: Biochemical marker assays measure: The predictive value of markers for the risk of cardiovascular events in chest pain measure: Multimarker approach to improve cardiovascular risk stratification sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Fondazione Policlinico Universitario "A. Gemelli" IRCCS status: RECRUITING city: Roma zip: 00168 country: Italy name: ANDREA PICCIONI, Dr. role: CONTACT phone: 0630153161 email: andrea.piccioni@policlinicogemelli.it lat: 41.89193 lon: 12.51133 hasResults: False
nctId: NCT06295965 id: RG1123813 id: NCI-2023-10315 type: REGISTRY domain: CTRP (Clinical Trial Reporting Program) id: FHIRB0020162 type: OTHER domain: Fred Hutch/University of Washington Cancer Consortium id: R01CA272594 type: NIH link: https://reporter.nih.gov/quickSearch/R01CA272594 briefTitle: Clonal Hematopoiesis in Ovarian Cancer Survivors and Risk of Secondary Blood Cancers overallStatus: RECRUITING date: 2024-01-02 date: 2028-12-31 date: 2031-12-31 date: 2024-03-06 date: 2024-03-12 name: University of Washington class: OTHER name: National Cancer Institute (NCI) briefSummary: This study is being done to investigate clonal hematopoiesis and therapy-emergent myeloid neoplasms in patients with ovarian cancers. Researchers want to identify risk factors for developing these blood cancers as well as if there is/are a genetic/environmental component(s) to developing blood cancer. conditions: Recurrent Fallopian Tube Carcinoma conditions: Recurrent Ovarian Carcinoma conditions: Recurrent Primary Peritoneal Carcinoma studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 2000 type: ESTIMATED name: Non-Interventional Study measure: Determine the correlation between baseline TP53m VAF in blood with CH expansion in OC patients measure: Identify risk of TMN for OC survivors with and without TP53m CH treated with platinum chemotherapy and PARP inhibitors measure: Define the trajectories of clonal evolution and mechanisms of transformation from non-cancerous TP53m to TMN sex: FEMALE stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Fred Hutch/University of Washington Cancer Consortium status: RECRUITING city: Seattle state: Washington zip: 98109 country: United States name: Swisher Lab Research Coordinators role: CONTACT phone: 206-616-8927 email: swisherlabrc@uw.edu name: Elizabeth Swisher role: PRINCIPAL_INVESTIGATOR lat: 47.60621 lon: -122.33207 hasResults: False
nctId: NCT06295952 id: 23-371 briefTitle: A Study of Pasireotide in People With Prolactinoma overallStatus: RECRUITING date: 2024-02-27 date: 2027-02 date: 2027-02 date: 2024-03-06 date: 2024-03-06 name: Memorial Sloan Kettering Cancer Center class: OTHER name: Evergreen Theragnostics name: Recordati Pharmaceutical company briefSummary: The researchers are doing this study to find out whether pasireotide is an effective treatment for people with prolactinoma who cannot receive dopamine agonist therapy. Another purpose of this study is to find out whether pasireotide is a safe treatment for people with prolactinoma. conditions: Prolactin-Producing Pituitary Tumor studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: This is an open label single-center pilot study. primaryPurpose: TREATMENT masking: NONE count: 10 type: ESTIMATED name: Pasireotide measure: biochemical response rate measure: radiographic response sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) status: RECRUITING city: Basking Ridge state: New Jersey zip: 07920 country: United States name: Eliza Geer, MD role: CONTACT phone: 646-608-3797 lat: 40.70621 lon: -74.54932 facility: Memorial Sloan Kettering Monmouth (Limited Protocol Activities) status: RECRUITING city: Middletown state: New Jersey zip: 07748 country: United States name: Eliza Geer, MD role: CONTACT phone: 646-608-3797 lat: 40.39652 lon: -74.09211 facility: Memorial Sloan Kettering Bergen (Limited Protocol Activities) status: RECRUITING city: Montvale state: New Jersey zip: 07645 country: United States name: Eliza Geer, MD role: CONTACT phone: 646-608-3797 lat: 41.04676 lon: -74.02292 facility: Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities) status: RECRUITING city: Commack state: New York zip: 11725 country: United States name: Eliza Geer, MD role: CONTACT phone: 646-608-3797 lat: 40.84288 lon: -73.29289 facility: Memorial Sloan Kettering Westchester (Limited Protocol Activities) status: RECRUITING city: Harrison state: New York zip: 10604 country: United States name: Eliza Geer, MD role: CONTACT phone: 646-608-3797 lat: 40.96899 lon: -73.71263 facility: Memorial Sloan Kettering Cancer Center status: RECRUITING city: New York state: New York zip: 10065 country: United States name: Eliza Geer, MD role: CONTACT phone: 646-608-3797 name: Andrew Lin, MD role: CONTACT phone: 212-639-8392 lat: 40.71427 lon: -74.00597 facility: Memorial Sloan Kettering Nassau (Limited Protocol Activities) status: RECRUITING city: Uniondale state: New York zip: 11553 country: United States name: Eliza Geer, MD role: CONTACT phone: 646-608-3797 lat: 40.70038 lon: -73.59291 hasResults: False
nctId: NCT06295939 id: CA code 016/2565, 012/2566 briefTitle: Effect of Social Support Program on Grief of Pregnancy Loss in Sunpasitthiprasong Hospital overallStatus: ACTIVE_NOT_RECRUITING date: 2022-04-29 date: 2024-03-15 date: 2024-05-31 date: 2024-03-06 date: 2024-03-29 name: Sanpasitthiprasong Hospital class: OTHER_GOV briefSummary: Research Question:
3. To explore other outcomes of pregnancy termination, such as complete abortion, uterine curettage, and post-miscarriage complications. conditions: Pregnancy Loss conditions: Grief conditions: Social Support studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: 1. The researcher provided information about a research project involving pregnant women diagnosed with fetal demise or abnormalities, who are recommended to undergo pregnancy termination at the third trimester abortion clinic.
4. Divide into groups of 45 individuals each, totaling 90 participants in the entire sample. primaryPurpose: OTHER masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 90 type: ACTUAL name: social support program name: Routine nursing care measure: The Perinatal Grief Assessment Questionnaire. sex: FEMALE minimumAge: 18 Years maximumAge: 45 Years stdAges: ADULT facility: Sanpasitthiprasong Hospital city: Ubon Ratchathani zip: 34000 country: Thailand lat: 15.23844 lon: 104.84866 hasResults: False
nctId: NCT06295926 id: K5236 briefTitle: Serplulimab Combined With CCRT for LS-SCLC. overallStatus: NOT_YET_RECRUITING date: 2024-02-25 date: 2027-01-25 date: 2027-12-31 date: 2024-03-06 date: 2024-03-06 name: Peking Union Medical College Hospital class: OTHER briefSummary: Small cell lung cancer(SCLC) has a poor prognosis and a relatively short overall survival time, urgently requiring innovative treatment strategies to improve the prognosis of such patients. Immunotherapy has become an important component of first-line therapy for extensive-stage small cell lung cancer (ES-SCLC). Studies have found that, compared to chemotherapy alone, the combination of Surlidumab with carboplatin and etoposide can extend the median overall survival in ES-SCLC to over 15 months. However, to date, research on the use of immunotherapy in combination with concurrent chemoradiotherapy (CCRT) in limited-stage small cell lung cancer (LS-SCLC) remains limited. This study aims to explore the clinical benefits of Surlidumab in combination with concurrent chemoradiotherapy in LS-SCLC and evaluate the safety of immunotherapy in combination with CCRT as first-line treatment for LS-SCLC. At the same time, it seeks to identify tumor-related biomarkers that can effectively predict the efficacy of immunotherapy and prognosis. conditions: Small Cell Lung Cancer studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 96 type: ESTIMATED name: Serplulimab measure: Progression free survival measure: Overall survival measure: Incidence of adverse events graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 measure: objective response rate (ORR) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital city: Beijing state: Beijing zip: 100730 country: China lat: 39.9075 lon: 116.39723 hasResults: False